Author of

• 12701

  +

  P3.12 - Poster Session 3 - NSCLC Early Stage (ID 206)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12717

    +

    P3.12-016 - Frequency in EGFR, K-RAS, BRAF and ALK mutations in a cohort of cancers: ALK translocations are more frequently seen in advanced disease (ID 2696)

    09:30 - 09:30  |  Author(s): I. Walker
    • Abstract

    Background
    Routine mutation testing for potential targeted therapy is a challenge in the management of lung cancer. As part of a feasibility study on the implementation of molecular testing in the United Kingdom, Cancer Research UK (CRUK) set up a stratified medicine program testing EGFR, K-RAS, BRAF mutations and ALK translocation on lung cancer samples. We present the result from the first ten months from two hospitals feeding into one diagnostic molecular laboratory.

    Methods
    Mutations detection in EGFR and KRAS genes was undertaken using cobas®4800 (Roche) and single-strand conformation analysis for BRAF gene. ALK translocations were screened using Vysis ALK break apart rearrangement probe.

    Results
    A total of 94 resections all (but one) in stages I - IIIA were analysed, with mutations found entirely within adenocarcinomas (n=64), with a frequency of mutations/translocation identification of 30% (K-RAS) , 12.5% (EGFR), 1.5% (ALK) and 1.5% (BRAF) (Figure 1). Over the same period, 360 biopsies from patients with non-resectable/advanced disease, were analysed, the majority being stage 4, with a frequency of 24% (K-RAS), 10%.6 (EGFR), 4.3% and 1.9% (Figure 2). Figure 1 Figure 2

    Conclusion
    The data suggest that frequency of K-RAS, EGFR and BRAF mutations are similar in early and advanced non-small cell carcinoma, however ALK translocations were observed to be more frequent in patients with advanced disease. This may have implications when considering which patients should undergo FISH testing for ALK translocation and entry into clinical trials. This study was funded by Cancer Research UK, Astra Zenica and Pfizer.